Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2683]

FDA approves the use of denosumab for bone cancer

FDA approves the use of denosumab for bone cancer

MRI detects early effects of chemotherapy on children's hearts

MRI detects early effects of chemotherapy on children's hearts

ASCO 2013: Two commonly used paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer

ASCO 2013: Two commonly used paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer

ASCO 2013: No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma

ASCO 2013: No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma

ASCO 2013: Bevacizumab extends survival for relapsed and advanced cervical cancer

ASCO 2013: Bevacizumab extends survival for relapsed and advanced cervical cancer

ASCO 2013: Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death

ASCO 2013: Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death

ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer

ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer

ASCO 2013: New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye

ASCO 2013: New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye

Matrix metalloproteinase-8 induces interleukin expression in breast cancer cells

Matrix metalloproteinase-8 induces interleukin expression in breast cancer cells

Intensified, liposomal anthracycline-based chemo regimen for children with leukaemia may offer high survival rates without added heart toxicity

Intensified, liposomal anthracycline-based chemo regimen for children with leukaemia may offer high survival rates...

More from ecancer